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Purpose: To evaluate the effect of two molecular weight grades of hydroxypropyl methylcellulose on the 
release characteristics of carvedilol phosphate matrix tablets. 
Methods: Matrix tablets containing carvedilol phosphate were prepared from 27 formulations in three 
batch series coded A, B and C, each containing 9 formulations. Each batch incorporated different ratios 
of two molecular weight grades of hydroxypropyl methylcellulose (Methocel® K4M CR and K15M CR) 
used as release retarding agents. Microcrystalline cellulose (Avicel PH 101), starch (Sta-Rx 1500) and 
lactose monohydrate were used as diluents in the formulations while the effect of sodium lauryl sulphate 
(wetting agent) was studied for some of the formulations. The tablets were characterized for carvedilol 
phosphate release in both simulated gastric and intestinal fluids. The data were subjected to different 
models in order to determine their release kinetics and mechanisms. 
Results: All the batches released more than 50 % of their carvedilol content in 12 h when Methocel® 
K4M CR and K15M CR constituted 18 % and 15 % of the matrix, respectively. Avicel® PH 101 
decreased while Starch 1500 and lactose monohydrate increased drug release. Drug release 
mechanism was predominantly diffusion. 
Conclusion:  By using varying combinations of two molecular weight grades of hydroxypropyl 
methylcellulose as the matrix, controlled or sustained release carvedilol tablets of varying release 
characteristics can be prepared. 
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Some of the goals in designing controlled 
release drug delivery systems (CRDDS) are 
to reduce the frequency of drug 
administration, provide uniform drug delivery 
and facilitate drug targeting [1]. The use of 
controlled release (CR) formulations offers 
many potential advantages, such as 
sustained blood levels, attenuation of 
adverse effects and improved patient 
compliance. It is important especially in the 
case of antihypertensive agents to maintain 
constant blood levels, as otherwise dose 
dumping may cause hypotension.  
 
Carvedilol is chemically (+)-1-(Carbazol-4-
yloxy)-3- {[2-(o-methoxy phenoxy) ethyl] 
amino}-propan-2-ol and is an antihyper-
tensive drug with multiple mechanisms of 
action. It acts as a non-selective β and -1 
adrenergic receptor blocker and it also has 
vasodilating property that is attributed mainly 
to its α-1 receptor antagonist activity [2,3]. Its 
conventional tablet dosage form is used to 
treat mild-to-moderate hypertension and 
angina pectoris [4]. Carvedilol base is 
practically insoluble in water (0.583 mg/L) 
and thus poorly absorbed from the 
gastrointestinal tract. It exhibits poor absolute 
bioavailability of 25-35% [5]. The half-life of 
the drug is 6 - 8 h [6]. Its very poor aqueous 
solubility indicates that its absorption is 
dissolution rate-limited which results in 
irregular and delayed absorption. Therefore 
conventional tablets are required to be 
administered 3 - 4 times a day. A suitable 
sustained release dosage form of carvedilol 
should provide prolonged action and better 
compliance by the patient. Recently, a 
phosphate salt of carvedilol was developed 
with improved aqueous solubility and 
chemical stability by protonation of the 
secondary amine as a salt [7].  
 
Methocel derivatives have been widely used 
in the design of complex controlled release 
systems because of their low toxicity, pH-
independent swelling and drug embedding 
ability [8]. These polymers are hydrophilic in 
nature and can retain active ingredients 
within its scaffold. Its retention ability, 
however, depends on the concentration or 
ratio of polymers used [9].  HPMC 4 and 
HPMC 15 are two typically used methocel 
polymers for the formulation of hydrophilic 
matrix systems, providing a robust 
mechanism for the slow release of drugs from 
oral solid dosage forms. They are suitable for 
preparing formulations with soluble or 
insoluble drugs and at high or low dosage 
levels. Hydration of polymers results in the 
formation of a gel layer that controls the 
release rate of drug from the core of matrix 
tablets [10].  
 
The aim of this work was to prepare matrix 
tablets containing carvedilol phosphate as a 
model drug, as well as either of two 
molecular weight grades (4 or 15 cps 
viscosity grade) hydroxypropyl methylcellu-
lose (HPMC) as matrix formers to control 
drug release. The mechanism of drug release 





Carvedilol phosphate (Aravinda Pharma-
ceuticals Limited, India) was a generous gift 
from Beximco Pharmaceuticals Limited, 
Bangladesh. Methocel® K4M CR and K15M 
CR, Avicel PH101, starch (Sta-Rx 1500, 
Colorcon,India), talc, and magnesium 
stearate were obtained from Dow Chemical’s 
Asia Pvt, Limited, India. All other chemicals 
were of analytical grade and were used as 
received. 
 
Preparation of carvedilol phosphate 
matrix tablets 
 
The carvedilol phosphate matrix tablets were 
prepared according to the formulations shown 
in Table 1. Drug, polymers and other excipients 
were weighed separately for 50 tablets per 
formulation for 27 proposed formulations in 
three batch series (each batch consists of 9 
formulations) coded as A (A1-A9), B (B1-B9) 
and C (C1-C9). The amount of carvedilol  
 
Halder et al 
Trop J Pharm Res, June 2012;11(3): 381 
Table 1: Composition of carvedilol phosphate matrix tablets 
 
Amount of Ingredients (mg)  















A1 37.5 37.5 131.3 0 0 0 
A2 30 37.5 138.8 0 0 0 
A3 45 37.5 122.5 0 0 1.25 
A4 37.5 30 138.75 0 0 0 
A5 37.5 45 123.8 0 0 0 
A6 45 30 130 0 0 1.25 
A7 30 45 131.3 0 0 0 
A8 30 30 146.3 0 0 0 
A9 45 45 115 0 0 1.25 
B1 37.5 37.5 0 131.3 0 0 
B2 30 37.5 0 138.8 0 0 
B3 45 37.5 0 122.5 0 1.25 
B4 37.5 30 0 138.75 0 0 
B5 37.5 45 0 123.8 0 0 
B6 45 30 0 130 0 1.25 
B7 30 45 0 131.3 0 0 
B8 30 30 0 146.3 0 0 
B9 45 45 0 115 0 1.25 
C1 37.5 37.5 0 0 131.3 0 
C2 30 37.5 0 0 138.8 0 
C3 45 37.5 0 0 122.5 1.25 
C4 37.5 30 0 0 138.75 0 
C5 37.5 45 0 0 123.8 0 
C6 45 30 0 0 130 1.25 
C7 30 45 0 0 131.3 0 
C8 30 30 0 0 146.3 0 
C9 45 45 0 0 115 1.25 
 
* Percent ratios of HPMC 4 and HPMC 15 used were: i. 15%: 15%, ii. 12%: 15%,  iii. 18%: 15%, iv. 15%: 12% v. 15%: 18% 
vi. 18%: 12%, vii. 12%: 18% viii. 12%: 12%  ix.18%: 18% of the total weight of the formulation 
 
phosphate, talc and Mg-stearate used in 
each formulation was 40 mg, 1.25 mg and 
2.5 mg, respectively, while the weight of each 
tablet was 250 mg. The required amounts of 
drugs and excipients were mixed together for 
15 min in a mixer; talc was added and mixed 
for another 1 min. The blended mass was 
transferred to the hopper of a laboratory 
hydraulic press fitted with a 10 mm flat-faced 
punch and die sets adjusted to a 
compressing weight of 250 mg. The tablets 
were compressed using a compression force 
and compression time of 5 tons and 20 s, 
respectively. Prior to compression, the die 
and punch surfaces were sufficiently 
lubricated with magnesium stearate. 
 
In vitro release studies 
 
In vitro drug release studies of the matrix 
tablets were carried out using a six-station 
USP XXII type II dissolution test apparatus 
(Eurolab, Germany) at 37 ± 0.5 °C and 100 
rpm speed in 900 ml of 0.1M hydrochloric 
acid (gastric simulated fluid, pH 1.3) as a 
dissolution medium for the first 2 h and in 
intestinal simulated fluid (900 ml, pH 6.8) for 
the next 10 h.  
 
Simulated gastric fluid (SGF) was prepared 
by diluting 11.4 ml of hydrochloric acid (32 %, 
w/v) with sufficient distilled water to make up 
to 1000 ml. One tablet from each formulation 
was placed in a basket and the equipment 
Halder et al 
Trop J Pharm Res, June 2012;11(3): 382 
was operated. Samples (10 ml) were 
withdrawn hourly over a period of 2 h, and 
the samples filtered The volume of 
dissolution medium was replenished with 10 
ml of fresh dissolution medium. The 
absorbance of the samples was measured 
with a single-beam UV-spectrophotometer 
(Shimadzu UV-1601, Japan) at 241 nm and 
the amount of drug released calculated. The 
release studies were conducted in triplicate, 
and mean values of drug released were 
plotted against time. 
  
After the 2 h test in SGF, 20 ml of NaOH (25 
%) was added to the SGF fluid and the pH 
adjusted to 6.8 ± 0.05 by the addition of 1.2 
ml ortho-phosphoric acid (1 N) to the 
remaining SGF fluid The operation was 
continued for 10 h, and samples were 
withdrawn, filtered and analysed as described 
for the test in SGF.  
 
Kinetic analysis of release data and 
mechanism of drug release 
 
In order to evaluate the kinetics and the 
mechanism of drug release from the 
formulations, the data obtained from the in 
vitro drug release studies were analyzed by 
zero-order [11] (cumulative percent of drug 
released vs time, Eq 1) and the Higuchi 
model [12] (cumulative percent of drug 
released vs square root of time) shown in Eq 
2  
Mt = M0 + k0t ....................................... (1) 
 
Mt = M0 + kHt1/2 ................................... (2) 
 
where Mt is the cumulative amount of drug 
released at any time, t, and M0 the dose of 
the drug incorporated in the delivery system, 
and k0 and kH are the rate constants for zero-
order and Higuchi models, respectively. 
 
The dissolution data were also fitted to the 
well-known exponential equation of Peppas 
et al [13] (Eq 3) which is often used to 
describe drug release behavior from 
polymeric systems. 
 
Mt/M  = ktn ……………………………….. (3) 
Where, Mt/M  is the fraction of drug released 
at time, t, k is the kinetic constant, and n is 
the diffusional exponent for drug release. The 
diffusional exponent, n, is dependent on the 
geometry of the device as well as the 
physical mechanism for release. A value of n 
= 0.45 indicates Fickian (case I) release; > 
0.45 but < 0.89 for non-Fickian (anomalous) 
release; and > 0.89 indicates super case II 
type of release. Case II generally refers to the 
erosion of the polymeric chain and 
anomalous transport (Non-Fickian) refers to a 
combination of both diffusion and erosion-




Data from the experiments were statistically 
evaluated by 2-tailed regression analysis 
using the Statistical Package for Social 
Science (SPSS) software for Windows 
(version 17, SPSS Inc., Chicago, Illinois, 
USA), and the multiple coefficient values (R2 
value) for non-linear drug release versus 
time. Square root or log time relationship was 
calculated and used as the parameter for 
determining statistical significance. Statistical 
analysis of the results was performed by 
using one-way analysis of variance (ANOVA) 
and the limit of significance was set at p < 




Drug release from matrix tablets 
 
The cumulative percent of carvedilol 
phosphate release from the matrix tablets of 
batch series ‘A’, ‘B’ and ‘C’ are shown in 
Figures 1, 2 and 3. The release data for 
formulations, A1, B1 and C1 showed 65.3, 
65.9 and 73.4 % drug release, respectively, 
in 12 h where the percent ratio of HPMC 4 
and HPMC 15 in the formulations were 1:1 
ratio.  Besides, the tablets of batch series “B” 
and “C” showed increased drug release 
compared to the tablets of batch series “A”. 
Starch 1500 and lactose monohydrate were 
used as the diluents for batch “B” and “C”, 
respectively. The release rates attained a 
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value of more than 50% in 12h when either 
HPMC 4 and HPMC 15 constituted at least 
15% of the matrix tablet. The tablets of 
formulations A3, A6 and A9 containing 
sodium lauryl sulfate showed increased 
dissolution rate which was mostly noticeable 
in the formulations where both polymers 
constituted 18 % of the matrix tablet. 
However, the dissolution rate was highest in 
formulations B3, B6, B9 and C3, C6, C9 
compared to A3, A6 and A9. The release 
data obtained were fitted into various release 
kinetic models and the outcome is listed in 
Table 2.  
 
 
Figure 1: Comparative release profile of carvedilol 
phosphate from matrix tablets based on (a) zero 
order and (b) Higuchi model. Key: batches A1 (♦), 
A2 (■), A3 (▲), A4 (x), A5 (*), A6 (●), A7 (□), A8 





Carvedilol phosphate is an important drug in 
the treatment of hypertension and stable 
angina pectoris. Besides its antioxidant and 
antiproliferative effects, it is reported to 
enhance one’s ability to combat the 
deleterious effects of sympathetic nervous 
system activation in heart failure [15, 16]. In 
view of its superiority in the treatment of 
hypertension, the preparation of a suitable 
sustained release dosage form might 
increase the efficacy of treatment and patient 
compliance by producing desirable blood 
concentrations and by minimizing the 

























Figure 2: Comparative release profile of carvedilol 
phosphate from matrix tablets based on (a) zero 
order and (b) Higuchi model. Key: batches B1 (♦), 
B2 (■), B3 (▲), B4 (x), B5 (*), B6 (●), B7 (□), B8 
(▪), B9 (▬).  
 
As there are no sustained release tablets of 
carvedilol phosphate available in the 
Bangladesh market, theoretical sustained 
release needed for once-daily (12-24 h) 
administration was calculated based on its 
pharmacokinetics as suggested by Wagner et 
al [17] and the release profiles of the 
formulated tablets were compared with the 
theoretical sustained release needed to 
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Figure 3: Comparative release profile of carvedilol 
phosphate from matrix tablets based on (a) zero 
order and (b) Higuchi model. Key: batches C1 (♦), 
C2 (■), C3 (▲), C4 (x), C5 (*), C6 (●), C7 (□), C8 
(▪), C9 (▬) 
 
controlled release product of carvedilol 
phosphate should contain a total dose of 40 
mg (initial dose - 20.5 mg; maintenance dose 
- 19.5 mg) and the drug should be released 
at a rate (k0) of 2.475 mg/h. Based on these 
doses and release rate (k0), an oral CR tablet 
of carvedilol phosphate should provide a 
release of 28.8 % in 1 h, 31.9 % in 2 h, 38.1 
% in 4 h, 50.4 % in 8 h, 62.8 % in 12 h, and 
100 % in 24 h [18,19]. The similarity factor 
(based on fit factor test) with theoretical 
profile was calculated and found to be 64.4, 
indicating good similarity. The rate of release 
of the formulations mostly complied with the 
theoretical sustained release formulation. The 
release rate of carvedilol phosphate from the 
tablets of batch series ‘B’ and ‘C’ increased 
as Starch 1500 and lactose monohydrate 
may act as disintegrants. Sodium lauryl 
sulfate was used as a surfactant to increase 
the dissolution rate of the matrix tablets; it 
indeed improved drug release rate in 
formulations C3, C6 and C9 compared to the 
formulations of ‘A’ and ‘B’ series and this may 
be due to the greater hydrophilic property of 
lactose monohydrate compared to 
microcrystalline cellulose and Starch 1500. 
The presence of sodium lauryl sulfate didn’t 
seem to be essential for an ideal formulation 
because formulations A5, B5 and C5 showed 
maximum drug release  of 70.1, 70.7 and 
78.2 %, respectively, after 12 h  compared to 
other formulations. This indicates that for 
effective controlled drug release, HPMC must 
constitute a minimum of 18 % of the tablet 
formulation. 
 
From the correlation coefficient values, 
Higuchi model was the best-fitting model for 
carvedilol phosphate release since higher 
“R2” values were obtained for the entire 
release process (see table 2), which indicates 
a diffusion-controlled release mechanism. 
The average R2 values in Higuchi kinetics for 
the tablets of batches A, B and C were 0.969, 
0.971 and 0.957, respectively, which were 
statistically significant at p ≤ 0.01 levels. On 
the other hand, the average R2 values (for 
zero-order kinetics) for the tablets of batches 
A, B and C were 0.831, 0.835 and 0.801, 
respectively, which were statistically 
significant at p ≤ 0.05 levels. Diffusion was 
related to transport of the drug from the 
dosage matrix into the dissolution fluid, 
depending on the concentration [20]. As drug 
concentration gradient rose, the drug 
diffusion pathway increased. This could 
explain why the drug diffused at a 
comparatively slower rate as the distance for 
diffusion increased, which is related to the 
square-root component of the Higuchi 
model[12]. In this work, the in vitro drug 
profiles of all the formulations could be best 
expressed by Higuchi model as the plots 
showed high linearity (R2 = 0.9793 to 
0.9922).  
 
To confirm it is diffusion-control mechanism, 
the data were fitted to Korsmeyer’s model 
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Table 2: Drug release kinetics for batch series “A”, “B” and “C” matrix tablets 
 
Zero-order Higuchi Korsmeyer-Peppas Batch code 
of 
formulation 
R2 k0 (h-1) R2 kH (h-1/2) R2 Diffusional 
exponent (n) 
A1 0.761 4.423 0.951 18.24 0.967 0.357 
A2 0.926 4.947 0.988 18.85 0.969 0.476 
A3 0.832 4.152 0.981 16.63 0.980 0.437 
A4 0.818 4.329 0.971 17.40 0.968 0.415 
A5 0.854 4.923 0.983 20.21 0.957 0.418 
A6 0.909 5.104 0.987 16.59 0.962 0.441 
A7 0.777 3.715 0.934 15.03 0.887 0.335 
A8 0.783 4.410 0.962 18.03 0.995 0.330 
A9 0.822 4.285 0.964 17.13 0.913 0.340 
B1 0.766 4.495 0.954 18.50 0.970 0.363 
B2 0.927 5.019 0.988 19.12 0.971 0.482 
B3 0.835 4.224 0.981 16.89 0.980 0.443 
B4 0.822 4.402 0.972 17.66 0.969 0.421 
B5 0.856 5.170 0.987 20.47 0.957 0.424 
B6 0.911 4.389 0.987 16.85 0.964 0.448 
B7 0.784 3.787 0.940 15.30 0.896 0.342 
B8 0.788 4.482 0.965 18.30 0.996 0.336 
B9 0.826 4.357 0.967 17.39 0.915 0.346 
C1 0.740 4.824 0.939 20.05 0.963 0.324 
C2 0.893 5.318 0.979 20.66 0.944 0.421 
C3 0.804 4.553 0.968 18.43 0.964 0.385 
C4 0.799 4.731 0.967 19.21 0.984 0.368 
C5 0.837 5.506 0.983 22.01 0.986 0.376 
C6 0.872 4.718 0.974 18.40 0.934 0.387 
C7 0.713 4.087 0.907 17.01 0.880 0.303 
C8 0.755 4.812 0.943 19.84 0.974 0.302 
C9 0.798 4.686 0.957 18.93 0.952 0.306 
 
k0 = zero-order rate constant; kH = Higuchi rate constant; R2 = Correlation coefficient 
 
 
linearity (R2 = 0.887 to 0.996), with diffusional 
exponent  (n) values ranging from 0.302 to 
0.482, indicating that diffusion was the 
dominant mechanism of drug release and 
that it was essentially quasi-Fickian diffusion 
(case I transport). The diffusional exponent of 
batches A2 (n = 0.476) and B2 (n = 0.482) 
indicates non-Fickian release, i.e., drug 
release is by coupling of Fickian diffusion and 
polymer matrix relaxation - the so-called 
anomalous diffusion; this also indicates that 
drug release is controlled by more than one 
process.  Similar results were observed by 
Basak et al [21] with matrix tablets of 
ambroxol hydrochloride containing HPMC; 
they considered the n value of less than 0.5 





HPMC 4 and HPMC 15 in varying proportions 
controlled carvedilol phosphate release 
effectively for 12 h. thus, the formulations 
should be suitable as a twice daily sustained 
release carvedilol phosphate tablet. In most 
cases, the release kinetics of carvedilol 
phosphate from the matrix tablets followed 
Higuchi kinetics. Furthermore, the rate of 
drug release is affected by the use of 
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